Inhibrx Biosciences (NASDAQ:INBX) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Inhibrx Biosciences (NASDAQ:INBX) in a research note published on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $245.00 price objective on the stock. HC Wainwright also issued estimates for Inhibrx Biosciences’ Q3 2026 earnings at ($2.14) EPS, Q4 2026 earnings at ($2.30) EPS, FY2026 earnings at ($8.93) EPS, Q1 2027 earnings at ($2.22) EPS, Q2 2027 earnings at ($2.15) EPS, Q3 2027 earnings at ($2.08) EPS, Q4 2027 earnings at ($2.02) EPS and FY2027 earnings at ($8.47) EPS.

A number of other equities analysts also recently commented on INBX. Weiss Ratings restated a “sell (d-)” rating on shares of Inhibrx Biosciences in a report on Tuesday, June 16th. Wall Street Zen cut shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $197.50.

Inhibrx Biosciences Stock Performance

Shares of NASDAQ INBX opened at $125.34 on Monday. The business’s 50-day moving average price is $93.07 and its two-hundred day moving average price is $90.11. The company has a debt-to-equity ratio of 12.58, a current ratio of 5.07 and a quick ratio of 5.07. Inhibrx Biosciences has a one year low of $25.27 and a one year high of $155.29. The company has a market capitalization of $1.85 billion, a P/E ratio of -14.11 and a beta of 3.51.

Inhibrx Biosciences (NASDAQ:INBX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). Analysts anticipate that Inhibrx Biosciences will post -9.91 earnings per share for the current fiscal year.

Institutional Trading of Inhibrx Biosciences

Large investors have recently made changes to their positions in the stock. Western Standard LLC bought a new stake in Inhibrx Biosciences during the second quarter valued at about $4,453,000. Parkman Healthcare Partners LLC acquired a new position in shares of Inhibrx Biosciences during the 2nd quarter worth about $24,346,000. Nicholas Investment Partners LP acquired a new position in shares of Inhibrx Biosciences during the 2nd quarter worth about $2,032,000. PSP Research LLC bought a new stake in Inhibrx Biosciences during the 4th quarter valued at approximately $505,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Inhibrx Biosciences during the 4th quarter valued at approximately $20,856,000. Institutional investors own 82.46% of the company’s stock.

Trending Headlines about Inhibrx Biosciences

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $245 price target, substantially above the recent trading level near $125. The target suggests significant potential upside and is likely the primary catalyst supporting the stock. HC Wainwright Begins Coverage on Inhibrx Biosciences
• Positive Sentiment: HC Wainwright projects that annual losses will narrow from an estimated $8.93 per share in fiscal 2026 to $8.47 per share in fiscal 2027. Its quarterly loss estimates also improve gradually through 2027, suggesting expectations for operating progress over time.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 25, unchanged from the prior report. This indicates no measurable short-selling pressure, although the unusual data provides little incremental insight into investor positioning.
• Negative Sentiment: Despite the bullish rating and target, Inhibrx Biosciences remains unprofitable. The broader consensus calls for a current-year loss of $10.88 per share, while HC Wainwright expects additional losses in every quarter covered through 2027. The company’s ability to deliver its pipeline and reduce cash burn remains important to sustaining the valuation.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.